These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
240 related articles for article (PubMed ID: 8547651)
1. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Hermine O; Haioun C; Lepage E; d'Agay MF; Briere J; Lavignac C; Fillet G; Salles G; Marolleau JP; Diebold J; Reyas F; Gaulard P Blood; 1996 Jan; 87(1):265-72. PubMed ID: 8547651 [TBL] [Abstract][Full Text] [Related]
2. Autologous stem-cell transplantation as consolidation therapy for diffuse large B-cell lymphoma patients with overexpression of bcl-2 protein. Results of the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trial LNH98-B2. Morel P; Gaulard P; Gisselbrecht C; Ferme C; Salles G; Tilly H; Brière J; Copin MC; Lederlin P; Hermine O; Theate I; Haioun C; Mounier N; Ann Oncol; 2008 Mar; 19(3):560-5. PubMed ID: 18096567 [TBL] [Abstract][Full Text] [Related]
3. Aggressive lymphomas with renal involvement: a study of 48 patients treated with the LNH-84 and LNH-87 regimens. Groupe d'Etude des Lymphomes de l'Adulte. Morel P; Dupriez B; Herbrecht R; Bastion Y; Tilly H; Delannoy A; Haioun C; Nouvel C; Bouabdallah K; Baumelou E Br J Cancer; 1994 Jul; 70(1):154-9. PubMed ID: 7517172 [TBL] [Abstract][Full Text] [Related]
4. Primary cutaneous large-cell lymphoma: analysis of 49 patients included in the LNH87 prospective trial of polychemotherapy for high-grade lymphomas. Groupe d'Etude des Lymphomes de l'Adulte. Brice P; Cazals D; Mounier N; Verola O; Neidhart-Berard AM; Remenieras L; Deconinck E; Doyen C; Hamelsand J; Molina T; Moulonguet I; Gisselbrecht C Leukemia; 1998 Feb; 12(2):213-9. PubMed ID: 9519784 [TBL] [Abstract][Full Text] [Related]
5. Is the small non-cleaved-cell lymphoma histologic subtype a poor prognostic factor in adult patients? A case-controlled analysis. The Groupe d'Etude des Lymphomes de l'Adulte. Diviné M; Lepage E; Brière J; Pautier P; Dupriez B; Lederlin P; Mineur P; Tilly H; Blanc M; Audhuy B; Herbrecht R; Coiffier B; Reyes F J Clin Oncol; 1996 Jan; 14(1):240-8. PubMed ID: 8558204 [TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of BCL-2 expression and bcl-2 major breakpoint region rearrangement in diffuse large cell non-Hodgkin's lymphoma: a British National Lymphoma Investigation Study. Hill ME; MacLennan KA; Cunningham DC; Vaughan Hudson B; Burke M; Clarke P; Di Stefano F; Anderson L; Vaughan Hudson G; Mason D; Selby P; Linch DC Blood; 1996 Aug; 88(3):1046-51. PubMed ID: 8704213 [TBL] [Abstract][Full Text] [Related]
7. Best treatment of aggressive non-Hodgkin's lymphoma: a French perspective. Coiffier B; Reyes F; Oncology (Williston Park); 2005 Apr; 19(4 Suppl 1):7-15. PubMed ID: 15934513 [TBL] [Abstract][Full Text] [Related]
8. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B. Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729 [TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte). Lepage E; Gisselbrecht C; Haioun C; Sebban C; Tilly H; Bosly A; Morel P; Herbrecht R; Reyes F; Coiffier B Ann Oncol; 1993 Sep; 4(8):651-6. PubMed ID: 7694634 [TBL] [Abstract][Full Text] [Related]
10. Quality of life-adjusted survival analysis of high-dose therapy with autologous bone marrow transplantation versus sequential chemotherapy for patients with aggressive lymphoma in first complete remission. Groupe d'Etude les Lymphomes de l'Adulte (GELA). Mounier N; Haioun C; Cole BF; Gisselbrecht C; Sebban C; Morel P; Marit G; Bouabdallah R; Ravoet C; Salles G; Reyes F; Lepage E Blood; 2000 Jun; 95(12):3687-92. PubMed ID: 10845898 [TBL] [Abstract][Full Text] [Related]
11. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Récher C; Coiffier B; Haioun C; Molina TJ; Fermé C; Casasnovas O; Thiéblemont C; Bosly A; Laurent G; Morschhauser F; Ghesquières H; Jardin F; Bologna S; Fruchart C; Corront B; Gabarre J; Bonnet C; Janvier M; Canioni D; Jais JP; Salles G; Tilly H; Lancet; 2011 Nov; 378(9806):1858-67. PubMed ID: 22118442 [TBL] [Abstract][Full Text] [Related]
12. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. André M; Mounier N; Leleu X; Sonet A; Brice P; Henry-Amar M; Tilly H; Coiffier B; Bosly A; Morel P; Haioun C; Gaulard P; Reyes F; Gisselbrecht C; Blood; 2004 Feb; 103(4):1222-8. PubMed ID: 14576060 [TBL] [Abstract][Full Text] [Related]
13. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol--a groupe d'Etude des lymphomes de l'Adulte study. Haioun C; Lepage E; Gisselbrecht C; Salles G; Coiffier B; Brice P; Bosly A; Morel P; Nouvel C; Tilly H; Lederlin P; Sebban C; Brière J; Gaulard P; Reyes F J Clin Oncol; 2000 Aug; 18(16):3025-30. PubMed ID: 10944137 [TBL] [Abstract][Full Text] [Related]
14. All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). Mounier N; Gisselbrecht C; Brière J; Haioun C; Feugier P; Offner F; Recher C; Stamatoullas A; Morschhauser F; Macro M; Thieblemont C; Sonet A; Fabiani B; Reyes F; Ann Oncol; 2004 Dec; 15(12):1790-7. PubMed ID: 15550584 [TBL] [Abstract][Full Text] [Related]
15. Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: the LNH87-1 study. Groupe d'Etudes des Lymphomes de l'Adulte. Tilly H; Mounier N; Lederlin P; Brière J; Dupriez B; Sebban C; Bosly A; Biron P; Nouvel C; Herbrecht R; Bordessoule D; Coiffier B J Clin Oncol; 2000 Mar; 18(6):1309-15. PubMed ID: 10715302 [TBL] [Abstract][Full Text] [Related]
16. Point mutations of the BCL-6 gene: clinical and prognostic correlation in B-diffuse large cell lymphoma. Vitolo U; Botto B; Capello D; Vivenza D; Zagonel V; Gloghini A; Novero D; Parvis G; Calvi R; Ariatti C; Milan I; Bertini M; Boccomini C; Freilone R; Pregno P; Orsucci L; Palestro G; Saglio G; Carbone A; Gallo E; Gaidano G Leukemia; 2002 Feb; 16(2):268-75. PubMed ID: 11840294 [TBL] [Abstract][Full Text] [Related]
17. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study. Copie-Bergman C; Gaulard P; Leroy K; Briere J; Baia M; Jais JP; Salles GA; Berger F; Haioun C; Tilly H; Emile JF; Banham AH; Mounier N; Gisselbrecht C; Feugier P; Coiffier B; Molina TJ J Clin Oncol; 2009 Nov; 27(33):5573-9. PubMed ID: 19786664 [TBL] [Abstract][Full Text] [Related]